Technology News and Research

RSS

Micrus Endovascular Corporation and Flexible Stenting Solutions to jointly develop flow diversion technology for neurovascular indications

Micrus Endovascular Corporation and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications using both Micrus and Flexible Stenting Solutions technology, development capabilities and intellectual property.

24 Aug 2009

Grants to grease e-health transition renew optimistic skepticism

Administration officials announced a new stimulus-funded federal grant program that will deploy $1.2 billion to help build health information technology infrastructure on Thursday.

24 Aug 2009

Two key circuits for controlling the cell's ability identified by UCSF researchers

UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.

24 Aug 2009

University of Michigan discovers new gene target for treating idiopathic pulmonary fibrosis

Researchers at the University of Michigan have discovered that targeting of a novel gene utilizing genetic and pharmacologic strategies was successful in treating pulmonary fibrosis in mice and will be developed for future testing in humans.

24 Aug 2009

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

24 Aug 2009

Research reveals that diarrheal bacteria can cause colon cancers

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

24 Aug 2009

Japanese research reveals that neural circuits in the mouse brain actively rearrange after stroke

Japanese research group led by Professor Junichi Nabekura in National Institute for Physiological Sciences, NIPS, Japan, found that, after cerebral stroke in one side of the mouse brain, another side of the brain rewires its neural circuits to recuperate from damaged neural function. The Japan Science and Technology Agency (JST) supported this study. They report their finding in Journal of Neuroscience, on August 12, 2009.

24 Aug 2009

Marin Catholic High School's new SAS system reduces the presence of illness-causing microorganisms

Marin Catholic High School (MCHS) and CSG, the worldwide leader in environmentally-beneficial surface treatments, today announced the school is the Bay Area's first education facility to integrate the Surface Antimicrobial System (SAS). The most environmentally friendly and long-lasting treatment of its kind, SAS has transformed 10,000 square feet of high-touch surfaces in Marin's athletic facility into materials that continuously inhibit the growth of harmful bacteria, mold, and fungi for three years.

24 Aug 2009

Sonomax Hearing Healthcare completes Phase I development of self-fit custom earpiece

Sonomax Hearing Healthcare Inc. (SHH:TSX Venture Exchange) announces objective, scientific proof of the company's ability to develop a technology to produce an off-the-shelf, self-fitting, custom earpiece.

24 Aug 2009

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

A cure for cystic fibrosis, HIV-fighting 'Trojan horses', new pharmaceuticals from the ocean. Chemical biologists use new and innovative approaches to discover medications of the future. On 24 August, some of the field's most prominent researchers will attend an international conference in Gothenburg, Sweden.

24 Aug 2009

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

iCo Therapeutics Inc. (TSX-V: ICO) today reported financial results for the quarter ended June 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

24 Aug 2009

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.

24 Aug 2009

ERF Wireless reports Q2 2009 financials

ERF Wireless (OTCBB:ERFW) has announced that the company has filed its Form 10-Q with the Securities and Exchange Commission reporting results for the second quarter ended June 30, 2009.

23 Aug 2009

Agreement between Kodak and MyMedicalRecords to provide enhanced electronic patient information online to doctors

A new independent software vendor (ISV) agreement between Kodak and MyMedicalRecords, Inc. (MMR), a subsidiary of MMR Information Systems, Inc. (OTCBB: MMRF), will enhance how doctors provide electronic patient information online.

22 Aug 2009

MarrowXpress System used for isolation and retrieval of bone marrow-derived adult stem cells

Celling Technologies collaborated with innovative cell processing expert, ThermoGenesis Corp., to deliver the most sophisticated point of care cell separation device on the market. The innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation and retrieval of bone marrow-derived adult stem cells.

21 Aug 2009

FDA approves Epocal's new glucose test on the epoc Blood Analysis System

Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new glucose test on the epoc Blood Analysis System.

21 Aug 2009

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached a joint venture agreement to begin production on a disposable protective face mask with its Asia Pacific region partner. The protective mask will incorporate ANI's proprietary NanoFense™ technology, a U.S. patent pending antimicrobial nanoparticle formulation.

21 Aug 2009

SRS appeals for EHR incentives in Washington

SRS, the EHR company that speaks on behalf of physicians, delivered a powerful message from physicians to policy-makers in Washington regarding the EHR incentives contained in the Economic Stimulus legislation.

21 Aug 2009

URAC extends support to develop and standardize health care quality improvement measures

URAC, the nation's leading healthcare accreditation and education organization, announced today that it has joined the more than 180 organizations supporting Stand for Quality. Stand for Quality is made up of organizations including AARP, the American Medical Association, National Consumers League, and the U.S. Chamber of Commerce that represent every segment of the health care industry.

21 Aug 2009

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.

21 Aug 2009

Technology News and Research

Micrus Endovascular Corporation and Flexible Stenting Solutions to jointly develop flow diversion technology for neurovascular indications

Grants to grease e-health transition renew optimistic skepticism

Two key circuits for controlling the cell's ability identified by UCSF researchers

University of Michigan discovers new gene target for treating idiopathic pulmonary fibrosis

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Research reveals that diarrheal bacteria can cause colon cancers

Japanese research reveals that neural circuits in the mouse brain actively rearrange after stroke

Marin Catholic High School's new SAS system reduces the presence of illness-causing microorganisms

Sonomax Hearing Healthcare completes Phase I development of self-fit custom earpiece

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

ERF Wireless reports Q2 2009 financials

Agreement between Kodak and MyMedicalRecords to provide enhanced electronic patient information online to doctors

MarrowXpress System used for isolation and retrieval of bone marrow-derived adult stem cells

FDA approves Epocal's new glucose test on the epoc Blood Analysis System

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

SRS appeals for EHR incentives in Washington

URAC extends support to develop and standardize health care quality improvement measures

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News